Read by QxMD icon Read

Stage IV cancer hypopharynx

Sonu Goyal, Tapesh Pounikar, Preety Jain, Ramesh Arya, Jagram Verma
INTRODUCTION: Both induction chemotherapy (ICT) followed by irradiation and concurrent chemotherapy and radiotherapy have been reported as valuable alternatives to total laryngectomy in patients with advanced larynx/hypopharynx cancer. MATERIALS AND METHODS: Of the 60 enrolled patients, randomly assigned into two groups (30 in each group) previously untreated patients with stages III to IV larynx/hypopharynx squamous cell carcinoma were assigned to received two cycles of ICT with interval of 3 weeks (a) Group A paclitaxel 175 mg/m 2 on day 1 and carboplatin 450 mg on day 2 (PC), (b) Group B docetaxel and cisplatin 75 mg/m 2 each on day 1 and ifosfamide 2 g/m 2 on day 1-3 along with mesna (docetaxel-ifosfamide-cisplatin)...
April 2016: Journal of Cancer Research and Therapeutics
Géraldine Descamps, Yasemin Karaca, Jérôme R Lechien, Nadège Kindt, Christine Decaestecker, Myriam Remmelink, Denis Larsimont, Guy Andry, Samantha Hassid, Alexandra Rodriguez, Mohammad Khalife, Fabrice Journe, Sven Saussez
PURPOSE: Despite the advent of concomitant chemoradiotherapy (CCRT), the prognosis of advanced head and neck squamous cell carcinoma (HNSCC) patients remains particularly poor. Classically, HNSCC, especially oropharyngeal carcinomas, associated with human papillomavirus (HPV) exhibits better treatment outcomes than HNSCCs in non-infected patients, eliciting a call for the de-escalation of current therapies. To improve the management of HNSCC patients, we aimed to determine the impact of active HPV infection on patient response, recurrence and survival after CCRT in a population of heavy tobacco and alcohol consumers...
October 2016: Journal of Cancer Research and Clinical Oncology
P Kannan, A Mukherji, K Saravanan, K S Reddy, S Vivekanandam, C Shamsudheen, V Santhosh
OBJECTIVE: To assess the change in the quality of life (QOL) in Oropharyngeal, Laryngeal and Hypopharyngeal cancer patients treated with concomitant boost radiotherapy by Volumetric Intensity Modulated Arc Therapy (VMAT) technique. METHODS: Thirty patients with oropharynx, larynx or hypopharynx cancers of stage II to IVA were treated with an Accelerated fractionation schedule using Concomitant boost. The dose given was 1.8Gy/fraction daily, 5 days a week to the large field for 28 fractions and a daily concomitant boost of 1...
May 2016: Gulf Journal of Oncology
Masahide Ikeguchi
PURPOSE: Locally advanced carcinomas arising in the hypopharynx have been traditionally treated by resection of the hypopharynx, larynx, and cervical esophagus. However, the prognosis of these patients is still low. In the present study, we retrospectively analyzed the long-term survival of patients with locally advanced hypopharyngeal squamous cell carcinoma (HSCC) reconstructed by jejunal graft. METHODS: Between 2004 and 2014, 68 patients with HSCC were treated at Tottori University Hospital...
September 2016: Langenbeck's Archives of Surgery
Nathan L Liang, Brian D Guedes, Umamaheswar Duvvuri, Michael J Singh, Rabih A Chaer, Michel S Makaroun, Ulka Sachdev
BACKGROUND: The purpose of this study was to examine outcomes of a patient cohort undergoing intervention for carotid blowout syndrome associated with head and neck cancer. METHODS: Patients with head and neck cancer who presented with carotid distribution bleeding from 2000 to 2014 were identified in the medical record. Primary outcomes were short- and midterm mortality and recurrent bleeding. Standard statistical methods and survival analysis were used to analyze study population characteristics and outcomes...
June 2016: Journal of Vascular Surgery
Takahide Taguchi, Goshi Nishimura, Masahiro Takahashi, Osamu Shiono, Masanori Komatsu, Daisuke Sano, Ken-Ichiro Yabuki, Yasuhiro Arai, Yukiko Yamashita, Kaoru Yamamoto, Yasunori Sakuma, Nobuhiko Oridate
BACKGROUND: For primary organ preservation, concurrent chemoradiotherapy (CCRT) is performed for advanced squamous cell carcinoma of the head and neck (SCCHN). In this organ-preservation setting with CCRT, surgery is reserved as a salvage treatment in cases of locoregional failure after CCRT. The purpose of the study was to review our experience with salvage surgery after CCRT for patients with SCCHN and to evaluate the effectiveness and prognostic factors affecting survival. METHODS: The records of patients with stage II-IVB SCC of the larynx, oropharynx, or hypopharynx treated with salvage surgery after CCRT between 1998 and 2012 were reviewed...
October 2016: International Journal of Clinical Oncology
John R Sims, Nathaniel L Robinson, Eric J Moore, Jeffrey R Janus
BACKGROUND: Transoral robotic surgery (TORS) has been shown to be both feasible and oncologically sound for use in early T classification hypopharyngeal cancers. The purpose of this study was to present our surgical technique for performing a transoral robotic hypopharyngectomy. METHODS: A 48-year-old man with a T2, N2a, M0 squamous cell carcinoma of the hypopharynx underwent a transoral robotic hypopharyngectomy and a left select neck dissection of levels II to IV...
April 2016: Head & Neck
Ricard Mesía, Silvia Vázquez, Juan J Grau, Jose A García-Sáenz, Alicia Lozano, Carlos García, Joan Carles, Antonio Irigoyen, Manel Mañós, Beatriz García-Paredes, Elvira del Barco, Miren Taberna, Yolanda Escobar, Juan J Cruz
PURPOSE: Despite treatment, prognosis of unresectable squamous cell carcinoma of the head and neck (SCCHC) is dismal. Cetuximab therapy has proven to increase the clinical activity of radiation therapy and chemotherapy in patients with locoregional advanced disease with an acceptable toxicity profile. We designed a phase 2 trial to evaluate the efficacy of docetaxel, cisplatin, and 5-fluorouracil (TPF) plus cetuximab (C-TPF) as an induction regimen in patients with unresectable SCCHN...
February 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Pascale A M Simons, Bram Ramaekers, Frank Hoebers, Kenneth W Kross, Wim Marneffe, Madelon Pijls-Johannesma, Dominique Vandijck
BACKGROUND: Compared with new technologies, the redesign of care processes is generally considered less attractive to improve patient outcomes. Nevertheless, it might result in better patient outcomes, without further increasing costs. Because early initiation of treatment is of vital importance for patients with head and neck cancer (HNC), these care processes were redesigned. OBJECTIVES: This study aimed to assess patient outcomes and cost-effectiveness of this redesign...
July 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Mathieu Leclerc, Eric Lartigau, Thomas Lacornerie, Jean-François Daisne, Andrew Kramar, Vincent Grégoire
PURPOSE/OBJECTIVE: The use of FDG-PET for target volume delineation has been validated by our group for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated by concomitant chemo-radiotherapy providing a strict methodology for image acquisition and segmentation. The aims of this study were (1) to confirm these results in a multicentric setting, and (2) to evaluate the clinical outcome in a prospective series of patients treated with FDG-PET scan-based radiotherapy planning...
July 2015: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Zoltán Takácsi-Nagy, Erika Hitre, Éva Remenár, Ferenc Oberna, Csaba Polgár, Tibor Major, Mária Gödény, János Fodor, Miklós Kásler
PURPOSE: Concurrent chemoradiotherapy (CRT) is the standard treatment for advanced head and neck squamous cell carcinoma. In this phase II randomized study, the efficacy and toxicity of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy (ICT) followed by concurrent CRT was compared with those after standard CRT alone in patients with locally advanced, unresectable head and neck cancer. PATIENTS AND METHODS: Between January 2007 and June 2009, 66 patients with advanced (stage III or IV) unresectable squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx, and larynx) were randomly assigned to two groups: one receiving two cycles of docetaxel, cisplatin, and 5-fluorouracil ICT followed by CRT with three cycles of cisplatin and one treated by CRT alone...
August 2015: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Maja Halgren Olsen, Charlotte Rotbøl Bøje, Trille Kristina Kjær, Marianne Steding-Jessen, Christoffer Johansen, Jens Overgaard, Susanne Oksbjerg Dalton
BACKGROUND: Socioeconomic differences in survival after head and neck squamous cell carcinoma (HNSCC) are among the greatest for any malignancy. To improve our understanding of the mechanisms by which socioeconomic position influences HNSCC survival, we investigated the association between socioeconomic position and advanced stage HNSCC at diagnosis. MATERIAL AND METHODS: Men and women with HNSCC diagnosed between 1992 and 2008 were identified in the Danish Head and Neck Cancer Group (DAHANCA) database, which contains detailed information on all cases of HNSCC treated in Denmark...
May 2015: Acta Oncologica
Jens Bentzen, Kasper Toustrup, Jesper Grau Eriksen, Hanne Primdahl, Lisbeth Juhler Andersen, Jens Overgaard
PURPOSE/OBJECTIVE: A phase II clinical trial evaluating the feasibility and outcome of treating locally advanced head and neck squamous cell carcinoma (HNSCC) with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. MATERIAL AND METHODS: A total of 227 patients with stage III or IV HNSCC of the larynx, oropharynx, hypopharynx, or oral cavity where included between January 2007 and December 2010. The prescribed radiotherapy (RT) dose was 66-68 Gy in 2 Gy fractions, 6 F/W...
July 2015: Acta Oncologica
Małgorzata Żmijewska-Tomczak, Piotr Milecki, Karolina Olek-Hrab, Katarzyna Hojan, Wojciech Golusiński, Anna Rucińska, Anna Adamska
INTRODUCTION: Radiotherapy (RT) in combination with chemotherapy is a standard of care for patients with head and neck squamous cell carcinoma (HNSCC). The RT is associated with side effects, which impact on quality of life (QoL). Thus, the aim of this prospective longitudinal study was to investigate the impact of RT on the QoL of patients with HNSCC during RT. MATERIAL AND METHODS: From September 2008 to February 2010, 205 patients with locally advanced HNSCC were enrolled...
December 22, 2014: Archives of Medical Science: AMS
Colin T Murphy, Thomas J Galloway, Elizabeth A Handorf, Lora Wang, Ranee Mehra, Douglas B Flieder, John A Ridge
BACKGROUND: The objective of this study was to identify trends and predictors of the time to treatment initiation (TTI) for patients with head and neck squamous cell carcinoma (HNSCC). METHODS: The National Cancer Database (NCDB) was reviewed for the following head and neck cancer sites: oral tongue, oropharynx, larynx, and hypopharynx. TTI was defined as the number of days from diagnosis to the initiation of definitive treatment and was measured according to covariates...
April 15, 2015: Cancer
Phuc Felix Nguyen-Tan, Qiang Zhang, K Kian Ang, Randal S Weber, David I Rosenthal, Denis Soulieres, Harold Kim, Craig Silverman, Adam Raben, Thomas J Galloway, André Fortin, Elizabeth Gore, William H Westra, Christine H Chung, Richard C Jordan, Maura L Gillison, Marcie List, Quynh-Thu Le
PURPOSE: We tested the efficacy and toxicity of cisplatin plus accelerated fractionation with a concomitant boost (AFX-C) versus standard fractionation (SFX) in locally advanced head and neck carcinoma (LA-HNC). PATIENTS AND METHODS: Patients had stage III to IV carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Radiation therapy schedules were 70 Gy in 35 fractions over 7 weeks (SFX) or 72 Gy in 42 fractions over 6 weeks (AFX-C). Cisplatin doses were 100 mg/m(2) once every 3 weeks for two (AFX-C) or three (SFX) cycles...
December 1, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Dorothy M Gujral, Aisha B Miah, Shankar Bodla, Thomas M Richards, Liam Welsh, Ulrike Schick, Ceri J Powell, Catharine H Clark, Margaret A Bidmead, Lorna Grove, Teresa Guerrero-Urbano, Shreerang A Bhide, Kate L Newbold, Kevin J Harrington, Christopher M Nutting
OBJECTIVES: We previously described dose-escalated intensity-modulated radiotherapy (IMRT) in squamous cell cancer of the larynx/hypopharynx (SCCL/H) to offer improved locoregional control with a low incidence of toxicity at 2 years. We now present outcome and safety data at 5 years. MATERIALS AND METHODS: A sequential cohort Phase I/II trial design was used. Patients with SCCL/H received IMRT at two dose levels (DL): DL1, 63 Gy/28 fractions to planning target volume 1 (PTV1) and 51...
November 2014: Oral Oncology
Savita Lasrado, Kuldeep Moras, George Jawahar Oliver Pinto, Mahesh Bhat, Sanath Hegde, Brijesh Sathian, Neil Aaron Luis
Standard therapy for advanced head and neck cancer consists of a combination of surgery and radiation. However, survival of this patient population has not improved during the past 20 years. Many different multimodality treatment schedules have been proposed, and chemotherapy is often used with the intent of organ preservation. The present study was intended to establish the efficacy of concomitant chemoradiation with a single agent carboplatin in advanced head and neck cancers.The objectives were to investigate the feasibility of concomitant administration of carboplatin, monitor acute toxicity during radiotherapy, and determine subacute side effects, such as wound healing following surgery after chemoradiotherapy...
2014: Asian Pacific Journal of Cancer Prevention: APJCP
Omar K Jilani, Prabhsimranjot Singh, A Gabriella Wernicke, David I Kutler, William Kuhel, Paul Christos, Dattatreyudu Nori, Albert Sabbas, Ks Clifford Chao, Bhupesh Parashar
PURPOSE: Management of locally advanced head and neck cancer (LAHNC) in the elderly is challenging due to multiple co-morbidities, poor organ function and performance status. The aim of this study was to evaluate efficacy of radiation therapy (RT) in elderly patients, defined as 65 years and older, with high-risk LAHNC. MATERIALS AND METHODS: An IRB approved retrospective chart review of elderly patients was performed, of whom 73 patients were selected for analysis...
October 2012: Journal of Geriatric Oncology
Waleed F Mourad, Kenneth S Hu, Daniel Shasha, Catherine Concert, Dan Ishihara, Wilson Lin, Mauricio E Gamez, John N Lukens, John J Lukens, Rania A Shourbaji, Magdalena Ryniak, Zujun Li, Bruce E Culliney, Azita S Khorsandi, Theresa Tran, Adam Jacobson, Spiros Manolidis, Stimson Schantz, Mark Urken, Mark S Persky, Louis B Harrison
AIM: To report the outcome of radiation therapy (RT) +/- chemotherapy in HIV-seropositive patients with Head and Neck Squamous Cell Carcinoma (HNSCC). PATIENTS AND METHODS: This is the largest single-Institution retrospective study to date, consisting of 73 HIV patients with HNSCC treated from January 1997-2010. The median age at RT, HIV diagnosis and the duration of patients being HIV seropositive were 51, 34, and 11 years, respectively. Seventy patients had SCC and one had submandibular salivary duct carcinoma...
December 2013: Anticancer Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"